MeSH term
Frequency | Condition_Probility | Animals | 251 | 0.0 |
Humans | 712 | 0.0 |
Influenza/*epidemiology | 2 | 7.0 |
Influenza A virus | 2 | 6.0 |
Influenza B virus | 2 | 7.0 |
Population Surveillance | 3 | 1.0 |
Seasons | 2 | 1.0 |
United States/epidemiology | 3 | 0.0 |
Aged | 63 | 0.0 |
Risk | 3 | 0.0 |
Time Factors | 31 | 0.0 |
Death, Sudden, Cardiac/*etiology | 2 | 11.0 |
Drug Interactions | 102 | 8.0 |
Drug Therapy, Combination | 9 | 0.0 |
Erythromycin/*adverse effects | 2 | 28.0 |
Adult | 196 | 0.0 |
Female | 248 | 0.0 |
Life Style | 2 | 1.0 |
Male | 347 | 0.0 |
Sex Factors | 11 | 0.0 |
Biological Markers | 5 | 0.0 |
Gene Library | 2 | 0.0 |
Molecular Sequence Data | 40 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Polymerase Chain Reaction | 22 | 0.0 |
*Polymorphism, Genetic | 11 | 0.0 |
Research Support, Non-U.S. Gov't | 378 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Alleles | 12 | 0.0 |
Base Sequence | 43 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 27 | 6.0 |
DNA/genetics | 2 | 0.0 |
Gene Expression | 16 | 0.0 |
Graft Survival | 2 | 0.0 |
Immunosuppressive Agents/*administration & dosage | 4 | 13.0 |
Kidney/enzymology | 2 | 1.0 |
Kidney Transplantation/*physiology | 2 | 4.0 |
Middle Aged | 133 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 5 | 27.0 |
Bile Acids and Salts/*metabolism | 3 | 7.0 |
Binding Sites/genetics | 2 | 0.0 |
Cell Line | 31 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 3 | 6.0 |
In Vitro | 94 | 1.0 |
Liver/drug effects/metabolism | 3 | 4.0 |
Mice | 64 | 0.0 |
Mice, Inbred C57BL | 10 | 0.0 |
Mice, Knockout | 12 | 0.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 9 | 50.0 |
Adolescent | 38 | 0.0 |
*Aryl Hydrocarbon Hydroxylases | 233 | 27.0 |
Biological Availability | 35 | 13.0 |
Biotransformation | 68 | 12.0 |
*Citrus | 9 | 21.0 |
Comparative Study | 144 | 0.0 |
Cytochrome P-450 CYP2D6/metabolism | 10 | 25.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 14 | 20.0 |
Dealkylation | 13 | 22.0 |
*Food-Drug Interactions | 3 | 13.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors/metabolism | 7 | 87.0 |
P-Glycoprotein/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Phenotype | 32 | 0.0 |
Reproducibility of Results | 14 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 19 | 38.0 |
Metabolic Clearance Rate | 26 | 7.0 |
Methylation | 14 | 2.0 |
Oxidoreductases, N-Demethylating/*metabolism | 60 | 73.0 |
Sensitivity and Specificity | 13 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 25 | 16.0 |
Genotype | 29 | 0.0 |
Hydroxylation | 55 | 15.0 |
Intestine, Small/enzymology/*metabolism | 4 | 80.0 |
Microsomes, Liver/metabolism | 19 | 10.0 |
Mixed Function Oxygenases/genetics/*metabolism | 5 | 10.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
Catalysis | 18 | 2.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 5 | 27.0 |
Isoenzymes/metabolism | 25 | 4.0 |
Microsomes, Liver/*enzymology | 51 | 26.0 |
Rats | 141 | 1.0 |
Rats, Sprague-Dawley | 64 | 2.0 |
Caco-2 Cells | 14 | 4.0 |
Coumarins/metabolism | 3 | 12.0 |
Hepatocytes/drug effects/enzymology | 4 | 40.0 |
Paclitaxel/metabolism | 2 | 25.0 |
Research Support, U.S. Gov't, P.H.S. | 209 | 0.0 |
Substrate Specificity | 51 | 2.0 |
Drug Interactions/physiology | 4 | 12.0 |
Imidazoles/*pharmacokinetics | 2 | 14.0 |
Microsomes, Liver/*metabolism | 47 | 27.0 |
Paclitaxel/*pharmacokinetics | 2 | 50.0 |
Chromatography, High Pressure Liquid | 70 | 4.0 |
Cytochrome P-450 Enzyme System/*metabolism | 117 | 23.0 |
Dogs | 25 | 2.0 |
Rabbits | 26 | 0.0 |
Rats, Inbred F344 | 9 | 2.0 |
Recombinant Proteins/metabolism | 24 | 0.0 |
Stereoisomerism | 16 | 4.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/*metabolism | 4 | 23.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Ethnic Groups | 3 | 1.0 |
Gene Frequency | 8 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Drug Design | 4 | 1.0 |
Oxidation-Reduction | 35 | 2.0 |
Administration, Oral | 49 | 5.0 |
Area Under Curve | 52 | 11.0 |
Cross-Over Studies | 37 | 6.0 |
Dose-Response Relationship, Drug | 49 | 0.0 |
Double-Blind Method | 22 | 1.0 |
P-Glycoprotein/antagonists & inhibitors | 4 | 40.0 |
Algorithms | 11 | 2.0 |
Risk Factors | 5 | 0.0 |
Pharmaceutical Preparations/*metabolism | 16 | 17.0 |
*Pharmacokinetics | 7 | 16.0 |
*Sex Characteristics | 3 | 2.0 |
Binding, Competitive | 7 | 0.0 |
COS Cells | 8 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 10 | 22.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Dimerization | 4 | 0.0 |
Gene Expression Regulation, Enzymologic | 14 | 1.0 |
Ligands | 5 | 0.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 4 | 3.0 |
Receptors, Steroid/metabolism | 5 | 12.0 |
Transcription Factors/metabolism | 6 | 0.0 |
Transfection | 27 | 0.0 |
Biological Transport | 6 | 0.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/physiology | 3 | 42.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
Gene Expression/drug effects | 3 | 0.0 |
Glucocorticoids/pharmacology | 5 | 3.0 |
Hela Cells | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Pharmacokinetics | 7 | 19.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 6 | 15.0 |
Enzyme Induction/drug effects | 40 | 10.0 |
Oxidoreductases, N-Demethylating/biosynthesis/*genetics | 6 | 75.0 |
Species Specificity | 42 | 1.0 |
Trans-Activation (Genetics)/*drug effects | 2 | 2.0 |
*Beverages | 9 | 20.0 |
Cytochrome P-450 CYP1A2/metabolism | 11 | 11.0 |
Cytochrome P-450 Enzyme System/metabolism | 34 | 14.0 |
*Flavanones | 4 | 16.0 |
Food-Drug Interactions | 6 | 20.0 |
Hydrocortisone/*analogs & derivatives/urine | 8 | 53.0 |
Mixed Function Oxygenases/metabolism | 23 | 16.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 28 | 33.0 |
Enzyme Induction | 44 | 7.0 |
Oxidoreductases, N-Demethylating/*biosynthesis | 15 | 83.0 |
Transcription Factors/genetics/physiology | 2 | 3.0 |
Coumarins/*metabolism | 2 | 13.0 |
Microsomes/enzymology/*metabolism | 2 | 33.0 |
Microsomes, Liver/enzymology/metabolism | 16 | 24.0 |
DNA Primers | 16 | 0.0 |
Intestine, Small/*enzymology | 6 | 30.0 |
Liver/*enzymology | 27 | 5.0 |
Transcription, Genetic | 9 | 0.0 |
Midazolam/*blood | 3 | 100.0 |
Predictive Value of Tests | 10 | 0.0 |
Antifungal Agents/*pharmacology | 7 | 14.0 |
Calcium Channel Blockers/*pharmacokinetics | 2 | 33.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors | 9 | 18.0 |
Enzyme Inhibitors/pharmacology | 61 | 2.0 |
Half-Life | 26 | 4.0 |
Injections, Intravenous | 12 | 1.0 |
Intestines/metabolism | 3 | 2.0 |
Ketoconazole/*pharmacology | 10 | 38.0 |
Liver/metabolism | 14 | 1.0 |
Nifedipine/*pharmacokinetics | 2 | 66.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors | 7 | 63.0 |
Liver/enzymology | 13 | 2.0 |
Aryl Hydrocarbon Hydroxylases/*physiology | 3 | 50.0 |
Microsomes/metabolism | 6 | 4.0 |
Oxidoreductases, N-Demethylating/*physiology | 5 | 50.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 25 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors | 6 | 37.0 |
Enzyme Inhibitors/administration & dosage | 2 | 15.0 |
Ketoconazole/administration & dosage | 2 | 100.0 |
Kinetics | 88 | 1.0 |
Microsomes, Liver/drug effects/enzymology | 28 | 28.0 |
Midazolam/administration & dosage/metabolism/pharmacokinetics | 2 | 100.0 |
Models, Animal | 3 | 1.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 24 | 80.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 29 | 24.0 |
Macaca fascicularis | 9 | 3.0 |
Ketoconazole/pharmacology | 32 | 34.0 |
*Genotype | 2 | 0.0 |
*Phenotype | 4 | 1.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 44 | 33.0 |
Microsomes, Liver/enzymology | 45 | 20.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 12 | 26.0 |
*Steroid 16-alpha-Hydroxylase | 13 | 7.0 |
Steroid Hydroxylases/antagonists & inhibitors/*metabolism | 2 | 22.0 |
Confidence Intervals | 3 | 0.0 |
Liver/drug effects/enzymology | 5 | 7.0 |
Diet | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology | 24 | 3.0 |
Microsomes, Liver/*drug effects/enzymology | 9 | 26.0 |
NADP/metabolism | 7 | 5.0 |
Steroid Hydroxylases/antagonists & inhibitors | 4 | 40.0 |
Acute Disease | 2 | 0.0 |
Case-Control Studies | 6 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Dosage Forms | 2 | 28.0 |
Drug Combinations | 4 | 0.0 |
Lung/metabolism | 2 | 1.0 |
Cytochrome P-450 Enzyme System/drug effects/*metabolism | 4 | 18.0 |
Tumor Cells, Cultured | 25 | 0.0 |
Child | 19 | 0.0 |
Child, Preschool | 12 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 6 | 5.0 |
Imidazoles/metabolism/*pharmacokinetics | 2 | 40.0 |
Models, Chemical | 7 | 1.0 |
Acetyltransferases/metabolism | 2 | 2.0 |
Aging/*metabolism | 7 | 3.0 |
Epoxide Hydrolases/metabolism | 3 | 18.0 |
Gene Expression Regulation, Enzymologic/*physiology | 2 | 2.0 |
Glucuronosyltransferase/metabolism | 3 | 11.0 |
Glutathione Transferase/metabolism | 7 | 0.0 |
Sulfotransferases/metabolism | 2 | 14.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Blotting, Western | 40 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Xenobiotics/*pharmacokinetics | 2 | 12.0 |
Enzyme Inhibitors/metabolism/*pharmacology | 3 | 17.0 |
Microsomes, Liver/drug effects/*enzymology/metabolism | 2 | 22.0 |
Rats, Wistar | 27 | 2.0 |
Midazolam/blood/*pharmacokinetics | 4 | 66.0 |
Antibiotics, Antitubercular/*pharmacology | 4 | 28.0 |
Hypnotics and Sedatives/pharmacokinetics | 4 | 100.0 |
Immunochemistry | 3 | 1.0 |
Organ Size/drug effects | 5 | 5.0 |
Protein Binding | 18 | 0.0 |
Rifabutin/*pharmacology | 2 | 66.0 |
Rifampin/*pharmacology | 16 | 32.0 |
Triazolam/pharmacokinetics | 2 | 66.0 |
Caco-2 Cells/drug effects/enzymology | 3 | 75.0 |
Hydroxytestosterones/metabolism | 3 | 37.0 |
Mixed Function Oxygenases/*biosynthesis | 6 | 30.0 |
P-Glycoprotein/*biosynthesis | 2 | 6.0 |
RNA, Messenger/biosynthesis | 9 | 0.0 |
Aged, 80 and over | 15 | 0.0 |
Colon/metabolism | 3 | 2.0 |
Oxidoreductases, N-Demethylating/genetics/*metabolism | 6 | 60.0 |
RNA, Messenger/*analysis | 6 | 1.0 |
African Continental Ancestry Group/genetics | 3 | 1.0 |
Cytochrome P-450 Enzyme System/*analysis/genetics | 5 | 62.0 |
European Continental Ancestry Group/genetics | 5 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Alternative Splicing | 3 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 6 | 5.0 |
Isoenzymes/genetics/metabolism | 6 | 4.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Swine, Miniature | 3 | 8.0 |
Dexamethasone/*pharmacology | 6 | 2.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 4 | 2.0 |
Hepatocytes/*drug effects/enzymology | 4 | 28.0 |
Mixed Function Oxygenases/*genetics | 7 | 4.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*physiology | 8 | 14.0 |
Receptors, Steroid/*physiology | 7 | 35.0 |
Reverse Transcriptase Polymerase Chain Reaction | 21 | 0.0 |
Caffeine/pharmacokinetics | 3 | 23.0 |
Chlorzoxazone/*pharmacokinetics | 2 | 33.0 |
Cytochrome P-450 CYP2E1/*metabolism | 4 | 6.0 |
Amoxicillin/therapeutic use | 2 | 15.0 |
Anti-Bacterial Agents/*adverse effects/therapeutic use | 2 | 33.0 |
Multivariate Analysis | 3 | 0.0 |
Clinical Trials | 6 | 0.0 |
Drug Resistance, Viral | 2 | 3.0 |
Intestines/*metabolism | 7 | 9.0 |
Liver/*metabolism | 12 | 2.0 |
Reference Values | 28 | 0.0 |
Calcitriol/*pharmacology | 3 | 1.0 |
Cells, Cultured | 60 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 17 | 24.0 |
Haplorhini | 3 | 1.0 |
Mixed Function Oxygenases/*biosynthesis/genetics | 2 | 22.0 |
Receptors, Calcitriol/genetics/metabolism | 2 | 11.0 |
Receptors, Retinoic Acid/metabolism | 2 | 2.0 |
Trans-Activation (Genetics) | 4 | 0.0 |
Chlorzoxazone/metabolism | 3 | 15.0 |
Cytochrome P-450 CYP2E1/metabolism | 5 | 11.0 |
Mephenytoin/metabolism | 3 | 18.0 |
Metoprolol/metabolism | 2 | 100.0 |
Midazolam/metabolism | 15 | 75.0 |
Oxidoreductases, N-Demethylating/metabolism | 37 | 69.0 |
Anti-Bacterial Agents/*pharmacokinetics | 3 | 60.0 |
Cytochrome P-450 Enzyme System/analysis/*metabolism | 3 | 42.0 |
Erythromycin/*pharmacokinetics | 3 | 50.0 |
*Liver Transplantation | 5 | 3.0 |
Oxidoreductases, N-Demethylating/analysis/*metabolism | 2 | 100.0 |
Dioxoles/*pharmacology | 2 | 25.0 |
Steroid Hydroxylases/metabolism | 11 | 17.0 |
Cytochrome P-450 CYP1A1/*antagonists & inhibitors | 2 | 33.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors | 2 | 13.0 |
Stilbenes/*pharmacology | 2 | 3.0 |
Insects | 4 | 2.0 |
Mass Fragmentography | 7 | 3.0 |
Testosterone/metabolism | 23 | 17.0 |
Electrocardiography/drug effects | 3 | 9.0 |
Amino Acid Sequence | 17 | 0.0 |
Models, Molecular | 4 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 3 | 1.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Xenobiotics/*metabolism | 10 | 18.0 |
Analysis of Variance | 14 | 0.0 |
Enzyme Activation | 4 | 0.0 |
Erythromycin/metabolism | 4 | 50.0 |
Estradiol/metabolism | 2 | 2.0 |
Recombinant Proteins | 4 | 0.0 |
Tamoxifen/metabolism | 2 | 66.0 |
Cytochrome P-450 CYP2D6/*metabolism | 10 | 28.0 |
Dextrorphan/metabolism | 2 | 100.0 |
Xenobiotics/*pharmacology | 5 | 17.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Variation (Genetics) | 6 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
*Gene Expression | 3 | 0.0 |
Gestational Age | 3 | 0.0 |
Immunoblotting | 16 | 0.0 |
Liver/*embryology/enzymology | 2 | 40.0 |
RNA, Messenger/analysis | 16 | 0.0 |
Cattle | 7 | 0.0 |
Isoenzymes/*metabolism | 16 | 5.0 |
Microsomes, Liver/*enzymology/metabolism | 4 | 13.0 |
Testosterone/*metabolism | 5 | 13.0 |
Antidepressive Agents, Tricyclic/blood/*pharmacokinetics | 2 | 100.0 |
Metabolic Clearance Rate/genetics | 2 | 22.0 |
Mixed Function Oxygenases/genetics | 2 | 5.0 |
Phenols/*pharmacology | 2 | 5.0 |
Immunosuppressive Agents/pharmacokinetics | 3 | 42.0 |
Intestinal Absorption/*physiology | 2 | 8.0 |
P-Glycoprotein/metabolism | 4 | 6.0 |
Troleandomycin/pharmacology | 29 | 50.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 3 | 1.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*metabolism | 5 | 20.0 |
Dexamethasone/pharmacology | 24 | 5.0 |
Hepatocytes/*drug effects/*enzymology | 2 | 28.0 |
Oxidoreductases, N-Demethylating/biosynthesis/*metabolism | 2 | 40.0 |
*Taxoids | 5 | 9.0 |
Mixed Function Oxygenases/biosynthesis/genetics | 3 | 30.0 |
Nifedipine/pharmacology | 2 | 5.0 |
Oxidoreductases, N-Demethylating/biosynthesis | 7 | 87.0 |
RNA, Messenger/biosynthesis/drug effects | 3 | 5.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 7 | 5.0 |
Receptors, Steroid/*metabolism | 4 | 7.0 |
Rifampin/pharmacology | 22 | 35.0 |
Steroid Hydroxylases/biosynthesis | 2 | 22.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Microsomes, Liver/drug effects/metabolism | 12 | 25.0 |
Phenacetin/metabolism | 3 | 27.0 |
Theophylline/metabolism | 3 | 23.0 |
DNA, Complementary/genetics | 7 | 0.0 |
Mixed Function Oxygenases/*metabolism | 23 | 16.0 |
Molecular Conformation | 2 | 0.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
European Continental Ancestry Group | 12 | 1.0 |
Intestinal Absorption | 2 | 1.0 |
Disease Models, Animal | 2 | 0.0 |
Intestines/*enzymology | 7 | 20.0 |
Pupil/drug effects | 3 | 37.0 |
Nitrophenols/metabolism | 2 | 9.0 |
Hydrocortisone/*analogs & derivatives/*urine | 8 | 61.0 |
ATP-Binding Cassette Transporters/*biosynthesis/genetics | 2 | 11.0 |
Down-Regulation | 3 | 0.0 |
Genes, Reporter | 3 | 0.0 |
Hepatocytes/metabolism | 3 | 3.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Multidrug Resistance-Associated Proteins/metabolism | 2 | 20.0 |
Plasmids/metabolism | 2 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Ribosomal Proteins/metabolism | 2 | 15.0 |
Up-Regulation | 2 | 0.0 |
Anti-Bacterial Agents/pharmacology | 9 | 7.0 |
Antifungal Agents/pharmacology | 9 | 23.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 6 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Macrolides | 2 | 8.0 |
Mutagenicity Tests | 3 | 1.0 |
Cytochrome P-450 Enzyme System/*physiology | 9 | 15.0 |
Dopamine Uptake Inhibitors/*metabolism | 2 | 100.0 |
Mixed Function Oxygenases/physiology | 4 | 33.0 |
Piperazines/*metabolism | 2 | 40.0 |
Troleandomycin/*pharmacology | 5 | 83.0 |
Cytochrome P-450 CYP1A1 | 6 | 14.0 |
Liver/drug effects/*enzymology | 6 | 15.0 |
Mice, Inbred Strains | 6 | 0.0 |
Midazolam/*pharmacokinetics | 7 | 63.0 |
Chemistry, Physical | 2 | 1.0 |
Indicators and Reagents | 7 | 2.0 |
Spectrophotometry, Ultraviolet | 10 | 5.0 |
Bile Acids and Salts/*biosynthesis | 2 | 13.0 |
Cytochrome P-450 Enzyme System/genetics/*physiology | 2 | 18.0 |
Mixed Function Oxygenases/*physiology | 6 | 19.0 |
Mutation | 2 | 0.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/*metabolism | 2 | 15.0 |
Indinavir/metabolism | 2 | 66.0 |
Molecular Structure | 8 | 1.0 |
Zidovudine/metabolism | 2 | 40.0 |
Cytochrome P-450 CYP2D6/genetics | 2 | 6.0 |
Isomerism | 2 | 0.0 |
Drug Monitoring/*methods | 2 | 10.0 |
English Abstract | 10 | 0.0 |
Antibodies | 2 | 0.0 |
Cytochrome P-450 CYP1A2/*metabolism | 6 | 7.0 |
Hydrolysis | 4 | 0.0 |
Microsomes, Liver | 2 | 20.0 |
Cell Culture Techniques | 2 | 0.0 |
Benzylamines/*pharmacokinetics | 2 | 100.0 |
Bicyclo Compounds, Heterocyclic/*pharmacokinetics | 2 | 100.0 |
Spectrum Analysis, Mass | 20 | 3.0 |
Hepatocytes/cytology/drug effects/*enzymology | 2 | 66.0 |
Recombinant Proteins/genetics/metabolism | 6 | 0.0 |
*Kidney Transplantation | 2 | 0.0 |
Tacrolimus/*pharmacokinetics | 2 | 50.0 |
*Gene Expression Regulation | 4 | 0.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Oxidation-Reduction/drug effects | 2 | 2.0 |
Plant Extracts/pharmacology | 5 | 12.0 |
Japan | 3 | 0.0 |
Tissue Distribution | 10 | 0.0 |
Drug Administration Schedule | 13 | 1.0 |
*Thiazolidinediones | 4 | 4.0 |
Biliary Tract/*metabolism | 2 | 28.0 |
Perfusion | 2 | 0.0 |
DNA, Complementary | 9 | 0.0 |
Histamine H1 Antagonists/*pharmacokinetics | 2 | 50.0 |
Microsomes/enzymology/metabolism | 4 | 23.0 |
Mixed Function Oxygenases/biosynthesis/*metabolism | 2 | 33.0 |
Prodrugs/*pharmacokinetics | 2 | 18.0 |
Blotting, Northern | 12 | 0.0 |
Kidney/metabolism | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 7 | 1.0 |
Oxidoreductases, N-Demethylating/*biosynthesis/genetics | 5 | 50.0 |
Pregnenolone Carbonitrile/pharmacology | 7 | 87.0 |
Receptors, Cytoplasmic and Nuclear/genetics/*metabolism | 3 | 6.0 |
Receptors, Steroid/genetics/*metabolism | 2 | 14.0 |
Cytochrome P-450 CYP1A1/*biosynthesis | 2 | 8.0 |
Omeprazole/*pharmacology | 3 | 12.0 |
*Species Specificity | 2 | 33.0 |
P-Glycoprotein/*metabolism | 6 | 7.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
Antibodies/pharmacology | 5 | 1.0 |
Cytochrome P-450 CYP1A1/metabolism | 3 | 4.0 |
Microsomes/enzymology | 10 | 9.0 |
Antibodies, Monoclonal/pharmacology | 6 | 0.0 |
Erythromycin/pharmacology | 7 | 43.0 |
Metabolic Detoxication, Drug | 6 | 7.0 |
Microsomes, Liver/drug effects/*metabolism | 8 | 20.0 |
Oxidoreductases/metabolism | 3 | 4.0 |
Tolbutamide/pharmacology | 2 | 20.0 |
HIV Protease Inhibitors/blood/*pharmacology | 2 | 100.0 |
Liver/drug effects/enzymology/metabolism | 2 | 16.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 4 | 25.0 |
Glucocorticoids/*pharmacology | 3 | 1.0 |
Oxidoreductases, N-Demethylating/biosynthesis/genetics/*metabolism | 2 | 66.0 |
Continental Population Groups | 3 | 1.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Midazolam/administration & dosage/blood/*pharmacokinetics | 4 | 80.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/metabolism | 3 | 9.0 |
Models, Biological | 4 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
*Gene Expression Regulation, Enzymologic/drug effects | 3 | 6.0 |
Oxidoreductases, N-Demethylating/*genetics | 9 | 20.0 |
Callithrix | 2 | 2.0 |
Drug Resistance, Multiple | 5 | 3.0 |
Oxidoreductases, N-Demethylating/genetics | 3 | 27.0 |
Brain/*enzymology | 2 | 1.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 2 | 13.0 |
Immunohistochemistry | 21 | 0.0 |
Histamine H1 Antagonists/*pharmacokinetics/pharmacology | 3 | 75.0 |
Linear Models | 6 | 1.0 |
Terfenadine/*pharmacokinetics/pharmacology | 3 | 100.0 |
Anti-HIV Agents/*pharmacology | 2 | 1.0 |
Inhibitory Concentration 50 | 4 | 1.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 9 | 12.0 |
Oxazines/pharmacology | 2 | 50.0 |
Triazolam/metabolism | 5 | 100.0 |
Aging/metabolism | 3 | 1.0 |
Chromatography, Gas | 4 | 4.0 |
Microsomes, Liver/enzymology/*metabolism | 12 | 15.0 |
Pregnancy | 7 | 0.0 |
Xenobiotics/pharmacokinetics | 2 | 28.0 |
African Continental Ancestry Group | 3 | 1.0 |
Hispanic Americans | 2 | 3.0 |
Immunosuppressive Agents/administration & dosage/blood/*pharmacokinetics | 5 | 62.0 |
Infusions, Intravenous | 8 | 1.0 |
Tacrolimus/administration & dosage/blood/*pharmacokinetics | 2 | 100.0 |
Probability | 2 | 0.0 |
Single-Blind Method | 3 | 1.0 |
Statistics, Nonparametric | 3 | 0.0 |
Anti-Anxiety Agents/*metabolism | 2 | 33.0 |
Aryl Hydrocarbon Hydroxylases/*drug effects | 2 | 50.0 |
Ethanol/*pharmacology | 6 | 5.0 |
Hydroxylation/drug effects | 3 | 8.0 |
Microsomes, Liver/*drug effects/metabolism | 4 | 30.0 |
Nifedipine/*metabolism | 2 | 50.0 |
Oxidoreductases, N-Demethylating/*drug effects | 3 | 75.0 |
Triazolam/*metabolism | 2 | 50.0 |
Vasodilator Agents/*metabolism | 2 | 33.0 |
Organ Specificity | 4 | 0.0 |
Seals, Earless/*metabolism | 2 | 66.0 |
Seawater | 2 | 20.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*genetics | 2 | 2.0 |
Receptors, Steroid/*genetics | 2 | 9.0 |
Oxidoreductases, N-Demethylating/drug effects/*metabolism | 2 | 50.0 |
Mixed Function Oxygenases/antagonists & inhibitors/genetics/*metabolism | 2 | 22.0 |
Omeprazole/pharmacology | 2 | 16.0 |
Quinidine/pharmacology | 11 | 25.0 |
Ritonavir/pharmacology | 3 | 25.0 |
Sulfaphenazole/pharmacology | 6 | 20.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 11 | 31.0 |
Mixed Function Oxygenases/*antagonists & inhibitors | 5 | 11.0 |
Antineoplastic Agents, Hormonal/pharmacology | 2 | 4.0 |
Microsomes, Liver/drug effects/*enzymology | 13 | 30.0 |
Microsomes/drug effects/*enzymology | 2 | 50.0 |
*Evolution, Molecular | 2 | 0.0 |
Fetus/enzymology | 2 | 7.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/metabolism | 8 | 72.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Mixed Function Oxygenases/immunology | 2 | 40.0 |
Cell Survival/drug effects | 6 | 0.0 |
Hepatocytes/drug effects/*enzymology | 3 | 27.0 |
Anti-Arrhythmia Agents/*pharmacokinetics | 3 | 50.0 |
Intestine, Small/cytology/*metabolism | 2 | 28.0 |
Breath Tests | 11 | 15.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 2 | 3.0 |
*Drug Interactions | 6 | 26.0 |
Cytochrome P-450 Enzyme System/classification/*genetics/metabolism | 2 | 100.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Risk Assessment | 2 | 0.0 |
Variation (Genetics)/*physiology | 2 | 16.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/*metabolism | 14 | 77.0 |
Vitamin E/*metabolism | 2 | 20.0 |
GABA Modulators/metabolism | 3 | 75.0 |
Central Nervous System Depressants/*pharmacology | 2 | 12.0 |
Chlorzoxazone/pharmacology | 2 | 33.0 |
Cysteine Proteinase Inhibitors/*pharmacokinetics | 2 | 100.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 4 | 21.0 |
Nifedipine/blood/*pharmacokinetics | 2 | 50.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 2 | 6.0 |
Alkylation | 3 | 4.0 |
Liver/cytology/*drug effects/enzymology | 3 | 25.0 |
Precipitin Tests | 3 | 0.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Ritonavir/*pharmacology | 4 | 50.0 |
Clofibrate/pharmacology | 3 | 14.0 |
Cytochrome P-450 CYP2D6/genetics/metabolism | 3 | 20.0 |
Microsomes, Liver/drug effects/enzymology/*metabolism | 5 | 27.0 |
Phenobarbital/pharmacology | 14 | 22.0 |
beta-Naphthoflavone/pharmacology | 2 | 6.0 |
Guinea Pigs | 5 | 0.0 |
Tritium/diagnostic use | 3 | 2.0 |
European Continental Ancestry Group/*genetics | 4 | 1.0 |
Polymorphism, Genetic | 8 | 0.0 |
Anti-Anxiety Agents/blood/*pharmacokinetics | 2 | 40.0 |
HIV Protease Inhibitors/*pharmacology | 4 | 14.0 |
Metabolic Clearance Rate/drug effects | 5 | 31.0 |
Liver/cytology/enzymology | 3 | 37.0 |
Statistics | 3 | 0.0 |
Biological Transport/drug effects | 3 | 1.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 4 | 13.0 |
Isoenzymes/biosynthesis/genetics | 4 | 8.0 |
*Transcription, Genetic | 3 | 0.0 |
Cimetidine/pharmacology | 3 | 13.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 5 | 13.0 |
*Plants, Medicinal | 2 | 2.0 |
Structure-Activity Relationship | 5 | 0.0 |
Midazolam/*metabolism | 4 | 57.0 |
Cytochrome P-450 CYP1A1/*metabolism | 2 | 6.0 |
Biopsy | 4 | 0.0 |
Isoenzymes/*antagonists & inhibitors | 2 | 6.0 |
Recombinant Proteins/antagonists & inhibitors/metabolism | 2 | 4.0 |
RNA, Messenger/*biosynthesis | 6 | 2.0 |
Pharmacogenetics/*methods | 3 | 17.0 |
Microsomes, Liver/*drug effects/*metabolism | 2 | 40.0 |
Oxidoreductases, N-Demethylating/drug effects | 2 | 100.0 |
Cytochrome P-450 CYP1A1/biosynthesis | 3 | 10.0 |
Smoking/*metabolism | 2 | 4.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 7 | 25.0 |
Affect/drug effects | 2 | 15.0 |
Psychomotor Performance/drug effects | 2 | 10.0 |
Sex Characteristics | 11 | 2.0 |
HIV Infections/*drug therapy | 2 | 0.0 |
Antitussive Agents/metabolism | 2 | 50.0 |
Cytochrome P-450 CYP2D6/*antagonists & inhibitors | 4 | 44.0 |
Dextromethorphan/metabolism | 3 | 27.0 |
Chromans/*pharmacology | 3 | 11.0 |
Hypoglycemic Agents/*pharmacology | 3 | 6.0 |
Thiazoles/*pharmacology | 3 | 5.0 |
HIV Protease Inhibitors/*metabolism | 3 | 60.0 |
Cyclosporine/administration & dosage/blood/*pharmacokinetics | 3 | 50.0 |
Cytochrome P-450 Enzyme System/*drug effects/metabolism | 5 | 35.0 |
Oxidoreductases, N-Demethylating/*drug effects/metabolism | 2 | 100.0 |
3T3 Cells | 2 | 0.0 |
Theophylline/analogs & derivatives/pharmacology | 3 | 13.0 |
DNA/biosynthesis | 2 | 0.0 |
Isoenzymes/antagonists & inhibitors/biosynthesis/metabolism | 3 | 75.0 |
Oxidoreductases, N-Demethylating/antagonists & | 2 | 66.0 |
Debrisoquin/metabolism | 2 | 20.0 |
Indinavir/*metabolism | 2 | 66.0 |
Quinine/pharmacology | 2 | 15.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Anti-Bacterial Agents/pharmacokinetics/pharmacology | 2 | 100.0 |
Regression Analysis | 7 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Chromatography, High Pressure Liquid/methods | 3 | 2.0 |
Ifosfamide/*metabolism | 2 | 50.0 |
Age Factors | 4 | 0.0 |
Anti-Anxiety Agents/*pharmacokinetics | 5 | 41.0 |
Oxidoreductases, N-Demethylating/analysis | 2 | 50.0 |
Liver/*drug effects/enzymology | 6 | 13.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Binding Sites | 5 | 0.0 |
Progesterone/metabolism | 2 | 2.0 |
Protein Conformation | 2 | 0.0 |
Alprazolam/*pharmacokinetics | 2 | 33.0 |
Quinine/*metabolism | 3 | 60.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis/*genetics | 2 | 100.0 |
Pharmaceutical Preparations/metabolism | 2 | 6.0 |
Isoenzymes/chemistry/*metabolism | 2 | 14.0 |
Anticholesteremic Agents/pharmacology | 2 | 4.0 |
Chickens | 2 | 0.0 |
Fluorometry | 2 | 2.0 |
Biological Transport, Active | 2 | 1.0 |
HIV Protease Inhibitors/*pharmacokinetics | 2 | 40.0 |
Indinavir/*pharmacokinetics | 2 | 100.0 |
Intestinal Absorption/*drug effects | 3 | 18.0 |
P-Glycoprotein/*physiology | 2 | 9.0 |
DNA Footprinting | 3 | 1.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 3 | 17.0 |
Lung/*metabolism | 2 | 2.0 |
Methylcholanthrene/pharmacology | 4 | 11.0 |
Mice, Inbred DBA | 2 | 0.0 |
Microsomes/*metabolism | 3 | 7.0 |
Mixed Function Oxygenases/genetics/metabolism | 2 | 9.0 |
Oxidoreductases, N-Demethylating/drug effects/metabolism | 2 | 50.0 |
Steroid Hydroxylases/genetics/metabolism | 2 | 18.0 |
Breath Tests/*methods | 3 | 42.0 |
Cytochrome P-450 Enzyme System/*analysis/antagonists & inhibitors | 3 | 75.0 |
Erythromycin/*metabolism | 4 | 80.0 |
Cytochrome P-450 Enzyme System/drug effects/metabolism | 2 | 28.0 |
*Macrolides | 2 | 5.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors/*metabolism | 7 | 77.0 |
Cell Line, Tumor | 4 | 0.0 |
*Protein Biosynthesis | 3 | 0.0 |
Hydroxytestosterones/*analysis/metabolism | 2 | 100.0 |
Mass Fragmentography/*methods | 2 | 14.0 |
Testosterone/*analysis/metabolism | 2 | 100.0 |
Biliary Tract/*enzymology | 2 | 100.0 |
Cytochrome P-450 CYP2E1/genetics/metabolism | 2 | 16.0 |
Epithelial Cells/enzymology | 2 | 5.0 |
Epoxide Hydrolases/genetics/metabolism | 3 | 50.0 |
Gallbladder/cytology/*enzymology | 2 | 100.0 |
Glutathione Transferase/genetics/metabolism | 3 | 2.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Antibiotics, Antitubercular/pharmacology | 3 | 33.0 |
Isoenzymes/drug effects/metabolism | 2 | 13.0 |
Swine | 9 | 0.0 |
Body Weight/drug effects | 2 | 1.0 |
Morpholines/*pharmacokinetics/pharmacology | 2 | 100.0 |
Anti-Bacterial Agents/*metabolism | 2 | 40.0 |
Pharmacogenetics | 2 | 1.0 |
Cross Reactions | 3 | 0.0 |
Oxidoreductases, N-Demethylating/biosynthesis/metabolism | 2 | 66.0 |
Indoles/metabolism/pharmacology | 3 | 50.0 |
Oxazines/metabolism | 3 | 13.0 |
Cohort Studies | 2 | 0.0 |
P-Glycoprotein/antagonists & inhibitors/*metabolism | 2 | 25.0 |
Mixed Function Oxygenases/*analysis/genetics | 4 | 80.0 |
Hypnotics and Sedatives/*metabolism | 5 | 71.0 |
Dextromethorphan/*metabolism/urine | 2 | 40.0 |
Enzyme Inhibitors/*metabolism/*pharmacology | 3 | 60.0 |
Liver Transplantation/immunology | 2 | 20.0 |
Benzodiazepines | 4 | 19.0 |
Antibodies, Blocking/pharmacology | 2 | 2.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*biosynthesis | 3 | 50.0 |
Liver/cytology/*enzymology | 4 | 21.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/*biosynthesis | 2 | 100.0 |
Anticonvulsants/*pharmacokinetics | 2 | 20.0 |
Cytochrome P-450 Enzyme System/biosynthesis | 3 | 15.0 |
Cytochrome P-450 Enzyme System/physiology | 5 | 19.0 |
Nifedipine/metabolism | 5 | 29.0 |
Cytochrome P-450 Enzyme System/*analysis/immunology | 2 | 50.0 |
Oxidoreductases, N-Demethylating/*analysis/immunology | 2 | 100.0 |
Pyridines/*metabolism | 2 | 20.0 |
Intestine, Small/metabolism | 2 | 3.0 |
Verapamil/pharmacology | 2 | 2.0 |
Catechols/*metabolism | 2 | 50.0 |
Liver/drug effects/enzymology/*metabolism | 3 | 60.0 |
Narcotics/*metabolism | 2 | 20.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood/*pharmacokinetics | 2 | 100.0 |
Mibefradil | 2 | 40.0 |
Pravastatin/blood/*pharmacokinetics | 2 | 100.0 |
Methylation/drug effects | 3 | 21.0 |
Lovastatin/metabolism/pharmacology | 2 | 100.0 |
Blood Proteins/metabolism | 4 | 1.0 |
Enzyme Inhibitors/*metabolism | 2 | 2.0 |
Cytochrome P-450 Enzyme System/*analysis | 6 | 31.0 |
Absorption | 3 | 2.0 |
Calibration | 2 | 1.0 |
Serotonin Uptake Inhibitors/*pharmacology | 4 | 13.0 |
Diazepam/*metabolism | 2 | 50.0 |
NADP/pharmacology | 2 | 9.0 |
Anti-Bacterial Agents/*pharmacology | 5 | 3.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/chemistry | 3 | 75.0 |
Diterpenes/pharmacology | 2 | 7.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics/metabolism | 3 | 20.0 |
Aging | 2 | 0.0 |
Caffeine/*pharmacokinetics | 2 | 11.0 |
Antioxidants/*pharmacokinetics | 2 | 66.0 |
Body Weight | 2 | 0.0 |
Oxidoreductases, N-Demethylating/physiology | 2 | 33.0 |
Bile/metabolism | 2 | 8.0 |
Chromatography, Liquid | 4 | 3.0 |
Glutathione/*metabolism | 2 | 3.0 |
Paclitaxel/*pharmacology | 2 | 3.0 |
Hepatoblastoma/pathology | 2 | 33.0 |
Liver Neoplasms/pathology | 3 | 6.0 |
Immunosuppressive Agents/*pharmacokinetics | 3 | 17.0 |
Tacrolimus/blood/*pharmacokinetics | 2 | 33.0 |
Glucuronates/metabolism | 3 | 11.0 |
Cholesterol/metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Microsomes/*enzymology | 6 | 13.0 |
Midazolam/pharmacokinetics | 9 | 75.0 |
Genes, MDR/*drug effects | 2 | 66.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Caco-2 Cells/drug effects/metabolism | 2 | 100.0 |
Midazolam/pharmacokinetics/*pharmacology | 2 | 100.0 |
Ritonavir/*pharmacokinetics/pharmacology | 2 | 100.0 |
Cytochrome P-450 CYP2D6/physiology | 3 | 42.0 |
Pregnatrienes/*pharmacokinetics | 2 | 50.0 |
Organ Culture Techniques | 3 | 0.0 |
Tamoxifen/*metabolism | 2 | 22.0 |
Neoplasms, Second Primary/chemically induced/*genetics | 2 | 33.0 |
United States | 3 | 0.0 |
Epoxy Compounds/*metabolism | 2 | 14.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/metabolism | 5 | 38.0 |
Oxidoreductases, N-Demethylating/*biosynthesis/metabolism | 4 | 66.0 |
*Signal Transduction | 3 | 0.0 |
Anti-HIV Agents/*metabolism | 3 | 33.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors | 2 | 13.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors | 2 | 28.0 |
Carcinogens/*toxicity | 2 | 1.0 |
Antipsychotic Agents/*metabolism | 3 | 50.0 |
Piperidines/*metabolism | 2 | 20.0 |
Antibodies, Viral/immunology | 2 | 2.0 |
Bone Neoplasms/pathology/virology | 2 | 33.0 |
Carcinoma, Squamous Cell/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cell Differentiation | 2 | 0.0 |
Cell Line, Tumor/metabolism/virology | 2 | 28.0 |
Cell Nucleus/virology | 2 | 15.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Cell Transformation, Viral/genetics | 2 | 8.0 |
Cervical Intraepithelial Neoplasia/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cervix Neoplasms/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cervix Uteri/pathology/*virology | 2 | 28.0 |
Disease Progression | 2 | 0.0 |
Epithelial Cells/ultrastructure/virology | 2 | 33.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Genes, Retinoblastoma | 2 | 2.0 |
Oncogene Proteins, Viral/biosynthesis/genetics/immunology/*physiology | 2 | 33.0 |
Osteosarcoma/pathology/virology | 2 | 33.0 |
Papillomavirus Infections/*genetics | 2 | 25.0 |
Papillomavirus, Human/genetics/*pathogenicity | 2 | 25.0 |
Retinoblastoma Protein/*metabolism | 2 | 1.0 |
Tumor Virus Infections/*genetics | 2 | 18.0 |
Hamsters | 10 | 0.0 |
Liver/cytology/*drug effects/*enzymology | 2 | 50.0 |
Oxygenases/metabolism | 4 | 50.0 |
17-Hydroxycorticosteroids/urine | 2 | 20.0 |
Cytochrome P-450 CYP2D6/*physiology | 2 | 33.0 |
Isoenzymes/antagonists & inhibitors | 2 | 4.0 |
Antibiotics, Antitubercular/metabolism/*pharmacology | 2 | 100.0 |
Carbon Radioisotopes | 4 | 4.0 |
Cytochrome P-450 Enzyme System/*blood | 2 | 66.0 |
Oxidoreductases, N-Demethylating/*blood | 2 | 100.0 |
Erythromycin/*pharmacology | 2 | 9.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors/physiology | 2 | 100.0 |
Sirolimus | 2 | 4.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*physiology | 6 | 40.0 |
Histamine H1 Antagonists/*metabolism | 2 | 28.0 |
Colonic Neoplasms | 2 | 1.0 |
Fetus | 5 | 0.0 |
Isoenzymes/biosynthesis/*metabolism | 2 | 22.0 |
Itraconazole/*pharmacology | 4 | 26.0 |
Blood Loss, Surgical/statistics & numerical data | 3 | 12.0 |
Blood Transfusion/utilization | 3 | 12.0 |
Cost-Benefit Analysis | 3 | 2.0 |
Hospital Costs/statistics & numerical data | 3 | 12.0 |
Length of Stay/statistics & numerical data | 3 | 8.0 |
Osteoarthritis, Knee/epidemiology/*surgery | 3 | 13.0 |
*Outcome Assessment (Health Care) | 3 | 6.0 |
Perioperative Care | 3 | 12.0 |
Postoperative Complications/epidemiology | 3 | 6.0 |
Turkey/epidemiology | 3 | 4.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Mixed Function Oxygenases/*analysis | 6 | 54.0 |
Mixed Function Oxygenases/chemistry | 2 | 28.0 |
Mixed Function Oxygenases/biosynthesis | 2 | 14.0 |
Sleep Stages/drug effects | 2 | 14.0 |
Enzyme Induction/*drug effects | 2 | 11.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Mixed Function Oxygenases/antagonists & inhibitors/immunology/*metabolism | 2 | 40.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Antipsychotic Agents/metabolism/*pharmacokinetics | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*drug effects | 2 | 15.0 |
*DNA Damage | 3 | 0.0 |
Lung/*enzymology | 3 | 4.0 |
Nifedipine/antagonists & inhibitors/metabolism | 2 | 100.0 |
*Gene Expression Regulation, Developmental | 3 | 0.0 |
Infant | 8 | 0.0 |
Infant, Newborn | 4 | 0.0 |
Coumarins/pharmacology | 2 | 10.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
Enzyme Induction/drug effects/physiology | 3 | 20.0 |
Cytochrome P-450 Enzyme System/analysis/*physiology | 2 | 50.0 |
Oxidoreductases, N-Demethylating/analysis/*physiology | 2 | 100.0 |
Antimalarials/*metabolism | 2 | 25.0 |
Antibody Specificity | 3 | 0.0 |
Thiazoles/*metabolism | 2 | 15.0 |
Dexamethasone/*metabolism | 2 | 50.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Isoenzymes/*biosynthesis | 2 | 3.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Drug Evaluation, Preclinical/methods | 2 | 6.0 |
Erythromycin/diagnostic use | 4 | 57.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology | 2 | 9.0 |
Cytochrome P-450 CYP1A2/*analysis | 2 | 100.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Liver/cytology/*metabolism | 2 | 2.0 |
Cytochrome P-450 Enzyme System/chemistry | 2 | 33.0 |
Disease Susceptibility | 2 | 0.0 |
Macaca mulatta | 5 | 1.0 |
China | 3 | 0.0 |
Steroid 16-alpha-Hydroxylase | 2 | 14.0 |
Mixed Function Oxygenases/antagonists & inhibitors | 5 | 17.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 7 | 6.0 |
Haplotypes | 2 | 0.0 |
Introns/genetics | 2 | 0.0 |
Quinolines/*metabolism | 2 | 11.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Triazoles/*pharmacology | 2 | 15.0 |
Acetaminophen/*toxicity | 2 | 33.0 |
Smoking | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Codeine/*metabolism | 2 | 66.0 |
Chloroguanide/*metabolism/pharmacokinetics | 2 | 100.0 |
P-Glycoprotein/*genetics | 5 | 10.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Isoenzymes/biosynthesis | 3 | 6.0 |
Drug Synergism | 4 | 0.0 |
Antipyrine/pharmacokinetics | 2 | 40.0 |
Isoniazid/pharmacology | 2 | 22.0 |
Metyrapone/*pharmacology | 2 | 33.0 |
Coturnix | 2 | 8.0 |
Liver/cytology/*drug effects/embryology/enzymology | 2 | 100.0 |
Cytochrome P-450 CYP2E1 | 32 | 31.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis | 4 | 25.0 |
Kidney/*enzymology | 3 | 4.0 |
Multigene Family | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Anti-Anxiety Agents/administration & dosage/*pharmacokinetics | 2 | 50.0 |
Steroid Hydroxylases/*analysis | 2 | 100.0 |
Isoenzymes | 5 | 2.0 |
Proadifen/pharmacology | 3 | 30.0 |
Cytochrome P-450 CYP2D6 | 4 | 5.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Antineoplastic Agents, Phytogenic/*pharmacokinetics | 2 | 22.0 |
Ketoconazole/metabolism/pharmacology | 2 | 100.0 |
Piperazines/*pharmacokinetics | 2 | 40.0 |
Liver/*enzymology/metabolism | 2 | 12.0 |
Carbon Radioisotopes/diagnostic use | 3 | 5.0 |
Protein Synthesis Inhibitors/diagnostic use | 3 | 100.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Antineoplastic Agents, Phytogenic/*metabolism | 2 | 20.0 |
Paclitaxel/*analogs & derivatives/*metabolism | 2 | 66.0 |
Benzoflavones/pharmacology | 2 | 4.0 |
Antineoplastic Agents/*metabolism | 2 | 7.0 |
Lipoxygenase Inhibitors/*metabolism | 2 | 100.0 |
Liver/*drug effects/metabolism | 3 | 6.0 |
1-Naphthylamine/analogs & derivatives/pharmacology | 2 | 66.0 |
Sertraline | 2 | 20.0 |
DNA, Complementary/biosynthesis | 3 | 5.0 |
Isoenzymes/physiology | 3 | 6.0 |
Cervix Uteri/*enzymology | 2 | 100.0 |
Epoxide Hydrolases/genetics/*metabolism | 2 | 40.0 |
Ethanolamines/metabolism | 3 | 16.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 12 | 26.0 |
CHO Cells | 2 | 0.0 |
Cytochrome P-450 CYP2B1 | 2 | 50.0 |
Intestine, Small/enzymology | 2 | 12.0 |
Isoenzymes/antagonists & inhibitors/immunology/*metabolism | 2 | 100.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Metyrapone/pharmacology | 3 | 23.0 |
Midazolam/analogs & derivatives/*metabolism | 2 | 100.0 |
Cyclosporine/metabolism | 2 | 22.0 |
Cytochromes b5/metabolism | 2 | 25.0 |
Enzyme Inhibitors | 2 | 2.0 |
Aldehyde Oxidase | 2 | 22.0 |
Aldehyde Oxidoreductases/*metabolism | 2 | 66.0 |
Dextromethorphan/*metabolism | 2 | 50.0 |
Cytosol/metabolism | 4 | 0.0 |
Receptors, Glucocorticoid/metabolism | 2 | 3.0 |
Omeprazole/*pharmacokinetics | 2 | 28.0 |
Cytochrome P-450 CYP1A2 | 2 | 2.0 |
Triazines/*metabolism | 2 | 50.0 |
RNA, Messenger/analysis/metabolism | 2 | 1.0 |
*DNA Adducts | 2 | 5.0 |
Biotransformation/drug effects/physiology | 2 | 50.0 |
Hydrocortisone/blood | 2 | 0.0 |
Endometrium/*enzymology | 2 | 18.0 |
Liver/embryology/*enzymology | 2 | 18.0 |
Fetus/metabolism | 2 | 1.0 |
Midazolam/pharmacology | 2 | 22.0 |
Liver/enzymology/metabolism | 2 | 6.0 |
Carbon Dioxide/metabolism | 2 | 6.0 |
Erythromycin/*diagnostic use | 2 | 66.0 |
Diltiazem/metabolism | 2 | 66.0 |
*Hypericum | 2 | 22.0 |
Diltiazem/pharmacology | 2 | 14.0 |
Testosterone/pharmacology | 2 | 3.0 |
Cyclosporine/pharmacokinetics | 2 | 40.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis | 2 | 18.0 |
Drug Monitoring | 2 | 4.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis/genetics | 2 | 28.0 |
Tacrolimus/*administration & dosage | 2 | 40.0 |
Gene Expression Regulation, Enzymologic/*genetics | 2 | 3.0 |
Body Mass Index | 2 | 0.0 |
*Gene Duplication | 2 | 1.0 |
Glucuronosyltransferase/genetics/metabolism | 2 | 15.0 |
Beverages | 3 | 11.0 |
HIV Infections/drug therapy | 2 | 4.0 |
HIV Protease Inhibitors/pharmacology | 3 | 23.0 |
Follow-Up Studies | 2 | 0.0 |
Survival Analysis | 2 | 0.0 |
Oxidoreductases, N-Demethylating/*genetics/*metabolism | 2 | 33.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis/genetics | 5 | 31.0 |
Gene Expression Regulation, Enzymologic/drug effects/physiology | 2 | 6.0 |
Digoxin/pharmacokinetics | 2 | 25.0 |
Paclitaxel/metabolism/*pharmacology | 2 | 50.0 |
Plant Preparations/pharmacology | 2 | 66.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Intestinal Absorption/drug effects | 2 | 11.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Liver/drug effects/*metabolism | 2 | 2.0 |
